Se han detectado varios errores en la traducción al inglés de la tabla 3 del artículo «Coronavirus: la emergencia geriátrica de 2020. Documento conjunto de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología y la Sociedad Española de Geriatría y Gerontología». La tabla correcta es:
Tabla 3.
Adverse cardiovascular effects of drugs investigated for COVID-19 treatment
| Chloroquine/hydroxychloroquine | Use carefully in patients with previous heart deasese, with QT at the upper limit of normal or under treatment with QT interval-prolonging agents*, electrolyte abnormalities (particularly hypokalemia or hypomagnesemia), clinically relevant bradycardia, arrhythmia, or severe heart failure. |
| The dosage must be adjusted in chronic kidney disease (glomerular filtration rate < 50mL/min) | |
| Lopinavir/ritonavir | Use carefully in patients with previous heart disease, with QT already at the upper limit of normal or under treatment with QT interval-prolonging agents*, electrolyte abnormalities (particularly, hypokalemia or hypomagnesemia), clinically relevant bradycardia, arrhythmia, or severe heart failure. |
| Azithromycin | Chronic kidney disease, fulminant, hepatitis; carefully in patients with arrhythmogenic disease (particularly, female and elderly patients): congenital or confirmed QT interval prolongation*, electrolyte abnormalities (particularly, hypokalemia or hypomagnesemia), clinically relevant bradycardia, arrhythmia, or severe heart failure. |
| Remdesivir | Hypotension during infusion. Unknown CV interactions |
| Tocilizumab | Hypertriglyceridemia, elevated transaminases. Unknown CV interactions |
| Interferon β-1b | Flu-like illness. Liver failure. No CV interactions reported |
| Cyclosporin | Hypertension, hyperlipidemia, hyperuricemia, hyperkalemia, hypomagnesemia |
CV, cardiovascular.
QT interval-prolonging agents: class I A (quinidine and procainamide) and III (dofetilide, amiodarone, and sotalol) antiarrhythmics, cisapride, terfenadine, antipsychotics such as pimozide, antidepressants such as citalopram, and fluoroquinolones such as moxifloxacin and levofloxacin.
Esta corrección se ha introducido en la versión electrónica del artículo el 12 de octubre.